---
figid: PMC5455995__nihms866728f1
figlink: /pmc/articles/PMC5455995/figure/F1/
number: F1
caption: 'RAS pathway is prognostic in breast cancer. (A) A schematic illustration
  of the EGFR/HER2/RAS signalling pathway is shown. The two upstream receptors, EGFR/HER2,
  the midstream kinases, phospho-ERK, and the most downstream signalling gatekeeper,
  SIAH E3 ligase, were highlighted. (B) SIAH and/or EGFR expression can be used to
  monitor tumour responses and identify resistant tumour clones post-NST and strategy
  patients. The therapy-induced changes in SIAH and EGFR expression, are highly prognostic
  in identifying effective/ineffective therapies, differentiating partial responders,
  identifying resistant tumour clones and predicting remission/relapse in breast cancer
  patients with lymph node metastases at first line therapy. EGFR, epidermal growth
  factor receptor; MAPK, mitogen-activate protein kinase; MEK, mitogen-activate protein
  kinase kinase; NST, neoadjuvant systemic therapy; RAF, rapidly accelerated fi brosarcoma;
  SIAH, seven in absentia homologue. (Adapted from van Reesema et al. SIAH and EGFR,
  two RAS pathway biomarkers, are highly prognostic in locally advanced and metastatic
  breast cancer. EBioMedicine 2016; 11: 183–198 []).'
pmcid: PMC5455995
papertitle: RAS pathway biomarkers for breast cancer prognosis.
reftext: Lauren L. Siewertsz van Reesema, et al. Clin Lab Int. 2016 Nov;40:18-23.
pmc_ranked_result_index: '8194'
pathway_score: 0.8013454
filename: nihms866728f1.jpg
figtitle: RAS pathway is prognostic in breast cancer
year: '2016'
organisms:
- Homo sapiens
ndex: 4b1f86ff-deb7-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5455995__nihms866728f1.html
  '@type': Dataset
  description: 'RAS pathway is prognostic in breast cancer. (A) A schematic illustration
    of the EGFR/HER2/RAS signalling pathway is shown. The two upstream receptors,
    EGFR/HER2, the midstream kinases, phospho-ERK, and the most downstream signalling
    gatekeeper, SIAH E3 ligase, were highlighted. (B) SIAH and/or EGFR expression
    can be used to monitor tumour responses and identify resistant tumour clones post-NST
    and strategy patients. The therapy-induced changes in SIAH and EGFR expression,
    are highly prognostic in identifying effective/ineffective therapies, differentiating
    partial responders, identifying resistant tumour clones and predicting remission/relapse
    in breast cancer patients with lymph node metastases at first line therapy. EGFR,
    epidermal growth factor receptor; MAPK, mitogen-activate protein kinase; MEK,
    mitogen-activate protein kinase kinase; NST, neoadjuvant systemic therapy; RAF,
    rapidly accelerated fi brosarcoma; SIAH, seven in absentia homologue. (Adapted
    from van Reesema et al. SIAH and EGFR, two RAS pathway biomarkers, are highly
    prognostic in locally advanced and metastatic breast cancer. EBioMedicine 2016;
    11: 183–198 []).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK8
  - ERBB2
  - KRAS
  - EGFR
  - ETS2
  - MAP2K3
  - MAP2K7
  - ETS1
  - NRAS
  - MAP2K4
  - MAP2K6
  - MAPK11
  - MAP2K5
  - ERBB4
  - MAP2K2
  - MAPK3
  - MAPK13
  - MAPK10
  - MAP2K1
  - HRAS
  - ARAF
  - BRAF
  - RAF1
  - MAPK9
  - MAPK1
  - MAPK14
  - MAPK12
  - ERBB3
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: EGFR/HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: K-RAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: EGFR/HER2
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ETS
  symbol: ETS
  source: bioentities_symbol
  hgnc_symbol: ETS2
  entrez: '2114'
- word: (MAPKK)
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K3
  entrez: '5606'
- word: (MAPKK)
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K7
  entrez: '5609'
- word: ETS
  symbol: ETS
  source: bioentities_symbol
  hgnc_symbol: ETS1
  entrez: '2113'
- word: ERBB/RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: (MAPKK)
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K4
  entrez: '6416'
- word: (MAPKK)
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K6
  entrez: '5608'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: (MAPKK)
  symbol: MAPKK
  source: bioentities_symbol
  hgnc_symbol: MAP2K5
  entrez: '5607'
- word: ERBB/RASPathwayActivationisPrognosticinBreastCancer
  symbol: ERBB
  source: bioentities_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: ERBB/RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERBB/RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: ERBB/RASPathwayActivationisPrognosticinBreastCancer
  symbol: ERBB
  source: bioentities_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: ERBB/RASPathwayActivationisPrognosticinBreastCancer
  symbol: ERBB
  source: bioentities_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: ERBB/RASPathwayActivationisPrognosticinBreastCancer
  symbol: ERBB
  source: bioentities_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5455995__F1
redirect_from: /figures/PMC5455995__F1
figtype: Figure
---
